Compare Bristol-Myers Squibb Co (BMY) vs iShares Core MSCI EAFE ETF (IEFA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs iShares Core MSCI EAFE ETF — how do they compare? Bristol-Myers Squibb Co trades at $56.99 (market cap $116.30B), while iShares Core MSCI EAFE ETF trades at $97.33. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while iShares Core MSCI EAFE ETF pays none, and iShares Core MSCI EAFE ETF is trading nearer its 52-week high, Bristol-Myers Squibb Co nearer its low. Which is the better fit depends on your goals.
| BMY | IEFA | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $62.37 | $98.56 |
52-Week Low | $42.60 | $81.70 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
IEFA trades at $96.15, down 1.1% on the day, with technical indicators showing a neutral to bearish short-term bias. The ETF provides exposure to developed international markets outside the US and Canada, offering diversification benefits amid S&P 500 concentration concerns. Recent news highlights IEFA's competitive 3.30% dividend yield and low 0.07% expense ratio compared to peers like VXUS and EEM.
The outlook remains balanced with potential upside from Fed rate cuts and international diversification benefits, offset by currency risks and developed market monetary policy tightening. IEFA's low-cost structure and dividend yield provide defensive characteristics, though performance depends heavily on international economic conditions and currency movements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About iShares Core MSCI EAFE ETF
IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.
Read more on IEFA →
